Results 171 to 180 of about 4,754 (217)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate. [PDF]

Postepy Dermatol Alergol, 2019
Omidian M, Jadbabaei M, Omidian E, Omidian Z.   +3 more
europepmc   +1 more source

Resistance of Leishmania (Viannia) Panamensis to Meglumine Antimoniate or Miltefosine Modulates Neutrophil Effector Functions. [PDF]

Front Immunol, 2018
Regli IB, Fernández OL, Martínez-Salazar B, Gómez MA, Saravia NG, Tacchini-Cottier F.   +5 more
europepmc   +1 more source

Visceral leishmaniasis in a patient with Down syndrome [PDF]

, 2006
AJAVOLASIT, P, COLOMBA, Claudia, GIORDANO, S, INFURNARI, Laura, SAPORITO, Laura, TITONE LANZA DI SCALEA, Lucina   +5 more
core  

Repurposing memantine as an oral therapy for visceral leishmaniasis: identification of direct leishmanicidal activity and immune system modulation in preclinical studies. [PDF]

Front Pharmacol
Gonçalves-Ozório G, Capilla LG, Emiliano YSS, Gervazoni LFO, De Luca PM, Almeida-Amaral EE.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies

International Journal of Pharmaceutics, 2008
The composition comprising the highly water-soluble drug meglumine antimoniate (MA) and beta-cyclodextrin (beta-CD) was shown previously to enhance the absorption of Sb by oral route and render MA orally active in a murine model of cutaneous leishmaniasis.
Frézard, F., Martins, P. S., Bahia, A. P., Le Moyec, L., de Melo, A. L., Pimenta, A. M., Salerno, M., da Silva, J. B., Demicheli, C.   +8 more
openaire   +5 more sources

Oxidative stress in mice treated with antileishmanial meglumine antimoniate

Research in Veterinary Science, 2013
In order to improve the understanding of the toxicity of pentavalent antimony (Sb(V)), we investigated the acute effects of meglumine antimoniate (MA) on the oxidative stress in heart, liver, kidney, spleen and brain tissue of mice. Levels of lipoperoxidation and protein carbonylation were measured to evaluate the oxidative status, whereas superoxide ...
D B, Bento, B, de Souza, A V, Steckert, R O, Dias, D D, Leffa, S E, Moreno, F, Petronilho, V M, de Andrade, F, Dal-Pizzol, P R, Romão   +9 more
openaire   +4 more sources

Physico-chemical characterization of meglumine antimoniate

Biometals, 1999
The leishmanicidal drug, meglumine antimoniate (MA), has been synthesized by the reaction of antimony oxyhydrated and N-methyl glucamine. Infrared and solid state NMR 13C analysis of MA and the ligand strongly suggests that antimony binds to N-methyl glucamine through the oxygen of C-3 carbon. Potentiometric titration indicated that, between pH 4.5 and
C, Demicheli, T L, de Figueiredo, S, Carvalho, R D, Sinesterra, J C, Lopes, F, Frézard   +5 more
openaire   +2 more sources

Embryotoxicity of meglumine antimoniate in the rat

Reproductive Toxicology, 2001
Meglumine antimoniate (MA) is a pentavalent antimonial (Sb(V)) drug used to treat leishmaniasis. Despite the fact that Sb(V) organic compounds have been used in clinical practice for more than 50 years, information on their safety during pregnancy is still scanty. This study was undertaken to evaluate the embryo/fetotoxicity of MA in the rat.
F J, Paumgartten, I, Chahoud
openaire   +2 more sources

Drug Hypersensitivity Syndrome Induced by Meglumine Antimoniate

The American Journal of Tropical Medicine and Hygiene, 2009
We report a case of drug hypersensitivity syndrome (drug reaction with eosinophilia and systemic symptoms [DRESS]) induced by parenteral meglumine antimoniate (Glucantime) in a 40-year-old man who traveled to Bolivia and was treated for mucocutaneous leishmaniasis.
Fakhri, Jeddi, Eric, Caumes, Marc, Thellier, Stéphane, Jauréguiberry, Dominique, Mazier, Pierre A, Buffet   +5 more
openaire   +2 more sources

Visceral leishmaniasis during pregnancy treated with meglumine antimoniate

Infection, 1995
Data on the efficacy and safety of pentavalent antimony in the treatment of visceral leishmaniasis during pregnancy are scanty. A case of visceral leishmaniasis in a 39-year-old woman in the second trimester of pregnancy is reported here. The patient was hospitalized in poor condition with high fever and pancytopenia which had lasted for 6 weeks.
UTILI, Riccardo, RAMBALDI A, TRIPODI MF, ANDREANA A.   +3 more
openaire   +3 more sources